Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments-Reference-Cited by-同舟云学术

Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments

Published:2021-11 Issue:11 Volume:38 Page:1839-1846
ISSN:0724-8741
Container-title:Pharmaceutical Research
language:en
Short-container-title:Pharm Res

Author:

Takemura Wataru,Tashiro Sho,Hayashi Marina,Igarashi Yuki,Liu Xiaoxi,Mizukami Yuki,Kojima Nana,Morita Takumi,Enoki Yuki,Taguchi Kazuaki,Yokoyama Yuta,Nakamura Tomonori,Matsumoto Kazuaki

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology

Link

https://link.springer.com/content/pdf/10.1007/s11095-021-03140-7.pdf

Reference31 articles.

1. Septimus EJ. Antimicrobial resistance an antimicrobial/diagnostic stewardship and infection prevention approach. Med Clin North Am. 2018;102(5):819–29.

2. Pitout JDD. Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae changing epidemiology and drug treatment choices. Drugs. 2010;70(3):313–33.

3. Willyard C. The drug-resistant bacteria that pose the greatest health threats. Nature. 2017;543(7643):15.